N/A N=60 Perianastomotic Drain After Gastrectomy (DRAG)
Gastric Cancer
Primary: a) Number of Participants With High Pain Levels (Using the Visual Analog Scale) — 31; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=15 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
N/A N=5 Gastrectomy, Eating Behaviour and GLP-1
Gastric Cancer · Dumping Syndrome
Primary: Nadir Blood Glucose — 3; 4.4 mmol/l — p=0.008
N/A N=15 Safety and Efficacy of Long Limb Roux-en Y Reconstruction
Diabetes Mellitus Type 2 in Nonobese · Gastric Cancer
Primary: Morbidity — 4 participants
N/A N=30 Ileal Interposition With Sleeve Gastrectomy for Control of Diabetes
Diabetes
Primary: Percentage of Participants Having Remission of Type 2 Diabetes — 76.66 Percentage of Participants
N/A N=150 Gastric Procedures for Obesity
Morbid Obesity
Primary: Change in Body Weight — -21.4; -36.6; -7.0 kg
N/A N=15 Assessment of Gastric Volume Reduction in Surgical Weight Loss Candidates
Obesity
Primary: Successful Gastric Plication Using Reduction Gastroplasty — 9; 6 participants
N/A N=4 Laparoscopic Sleeve Gastrectomy With Endoscopic Visualization
Morbid Obesity
Primary: Proportion of Procedures Completed With Successful Endoscopic Visualization. — 4 participants
N/A N=100 Gastric Ultrasound
Surgery
Primary: Aspiration Risk Grade — 30; 30; 20; 9 Participants
N/A N=72 Randomized Comparison of Laparoscopic Sleeve Gastrectomy and Gastric Bypass for Morbid Obesity
Morbid Obesity · Metabolic Syndrome X · Diabetes Mellitus
Primary: Excess Weight Loss From Baseline — 67.8; 64.2 percentage of EWL
N/A N=60 Endostapler Sleeve Gastrectomy Study
Obesity
Primary: Intraoperative Endoscopic Staple Line Bleeding Score — 1.63; 2.00 score on a scale
N/A N=34 Food Preference Following Bariatric Surgery
Obesity
Primary: Total Food Intake (Lunch Buffet) at 24 Months — 2540.1; 721 kJ
N/A N=35 Gastric Tissue Stapler Comparison Study
Gastric Resection
Primary: Pressure Evaluation — 126; 163 mmHg
Phase 3 N=90 Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy
Pain · Postoperative Depression
Primary: Change in Pain Scores — 1.45; 1 score on a scale
Phase 2 N=27 Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology
Gastric Adenocarcinoma · Esophagogastric Junction · Gastric Cancer
Primary: Overall Survival (OS) — 11.96 Months
N/A N=25 Use of Radiofrequency Ablation for RGB Salvage
Obesity
Primary: Excess Body Weight Loss After RFA Treatment — 28.36 percentage of EBWL
N/A N=592 Residual Gastric Volume Measured by Ultrasound in Diabetic Surgical Population Versus Non-diabetic Surgical Population.
Diabetes Mellitus
Primary: Residual Gastric Volume — 22.1; 33.1; 40.2 mL — p=<0.05
N/A N=355 Evaluation of Endostapled Anastomoses for Laparoscopic Gastric Bypass (EEA-LGB)
Morbid Obesity
Primary: Number of Participants With Postoperative Gastrointestinal Hemorrhage — 13; 39 participants
N/A N=10 Natural Orifice Transgastric Endoscopic (NOTES) Transgastric Diagnostic Peritoneoscopy With Laparoscopic Assistance
Abdominal Adhesions
Primary: Completion of Diagnostic Peritineoscopy — 8 Participants
N/A N=53 Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass
Gastroesophageal Reflux Disease · Morbid Obesity
Primary: Number of Participants Presenting Reflux Symptoms — 31; 8; 5 participants — p=<0.001
N/A N=106 Endoscopic vs. Suction Device Calibration in Sleeve Gastrectomy
Gastrectomy · Obesity
Primary: Number of Staple Load Firings — 5.26; 5.42 Number of staples
Phase 2 N=30 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
Gastric Cancer · Stomach Cancer
Primary: Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab — 40 percentage of paticipants
N/A N=63 Gastric Outlet Obstructions Tailored Covered Stents for GOO
Gastric Outlet Obstruction
Primary: Efficiency of Stents — 1; 7 participants
N/A N=22 Diabetes and Gastric By- Pass
Type 2 Diabetes
Primary: Response in Glucose AUC at Baseline vs. Following Gastric Bypass Surgery — 61647.0; 59476.1 mg/dL*min
N/A N=62 Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge
Hypoglycemia · Obesity
Primary: Mean Serum Glucose Levels — 123.1; 157.5; 103.2; 138 mg/dl
Phase 2 N=39 Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
Gastric Cancer
Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants
Phase 3 N=58 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
Gastroparesis
Primary: Symptom of Vomiting Associated With Gastroparesis — 1.82; 2.68; 0.17; 1.20 Patient Self-reported Symptom Score
N/A N=5 Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically
Arterial Embolization · Other Surgical Procedures · Obesity
Primary: Body Weight Average 6 Months Post-Procedure — 237.6 lbs.
Phase 4 N=96 The Effect of Deep Block Versus Moderate Block on the Stress Response After Laparoscopic Gastrectomy
Neuromuscular Blockade
Primary: IL-6 — 84; 70.14 pg / ml
N/A N=208 Multicenter Endoscopic Sleeve Gastrectomy (ESG) Trial (MERIT Trial)
Obesity · Hypertension · Diabetes Mellitus, Type 2
Primary: Percentage of Excess Weight Loss (EWL) — 3.2; 49.2; 44.1 percentage of EWL